EUCTR2021-000136-59-BG进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of Three Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatment of Hereditary Angioedema Type I or II
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Male or female subjects 18 years of age and older.
- •2) Confirmed diagnosis of HAE type I or II at any time in the medical history.
- •3) Subject has access to and ability to use conventional treatment for HAE attacks.
- •4) Subject is willing to cease any current medications being taken for HAE prophylaxis and Investigator determines that doing so would not place the subject at any undue safety risk.
- •5) Subject’s last dose of attenuated androgens was at least 28 days prior to randomization.
- •6) During the Run-in Period subject meets one of the following criteria:
- •a) Two Investigator-confirmed attacks in the first 4-week period.
- •b) Three Investigator-confirmed attacks in =8 weeks.
- •7) Subjects who are fertile and heterosexually active must adhere to contraception requirements throughout the trial as follows:
- •a) Female subjects must agree to use at least one highly effective contraception method from the Screening Visit until the end of the trial. Highly effective methods of contraception include:
- •i) Progestogen-only hormonal contraception associated with inhibition of ovulation: oral/injectable/implantable (hormonal contraception that contains estrogen including ethinylestradiol is excluded per Exclusion 4).
- •ii) Intrauterine device (IUD).
- •iii) Intrauterine hormone–releasing system (IUS).
- •iv) Bilateral tubal occlusion.
- •v) Vasectomized partner (provided that the partner is the sole sexual partner of the female subject of childbearing potential and that the vasectomized partner has received medical assessment of surgical success).
- •b) Male subjects with a female partner of childbearing potential must agree to use condoms for the entire Treatment Period AND for 90 days following the final dose of investigational medicinal product (IMP). Female partners are encouraged to use contraception as outlined in Inclusion 7a) from the Screening Visit until the end of the trial. Hormonal contraception that contains estrogen including ethinylestradiol is acceptable for the female partner.
- •8) Subjects who are not fertile or not sexually active, as defined below, do not require contraception.
- •a) Subjects who refrain from heterosexual intercourse during the trial if the reliability of the heterosexual abstinence has been evaluated in relation to the duration of the clinical trial and is the preferred and usual lifestyle of the subject.
- •b) Male subjects who are surgically sterile (e.g. vasectomized with medical assessment of surgical success).
- •c) Female subjects who are surgically sterile (e.g. status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 46
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1) Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria.
- •2) A clinically significant history of poor response to C1-INH therapy or plasma kallikrein inhibitor therapy, for the management of HAE, in the opinion of the Investigator.
- •3) Use of angiotensin-converting enzyme (ACE) inhibitors after the Screening Visit or within 7 days prior to randomization.
- •4) Any estrogen containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) after the Screening Visit or within 7 days prior to randomization.
- •5) Use of narrow therapeutic index drugs metabolized by CYP3A4 or CYP2C9 or transported by OAT1, OCT2, and OATP1B1 starting at screening, as determined by the Investigator.
- •6) Use of strong CYP3A4 inhibitors and inducers during participation in the trial, starting at the Screening Visit. Note: These medications include but are not limited to the following: Inhibitors: boceprevir, clarithromycin, cobicistat, dasabuvir, denoprevir, elvitegravir, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, and voriconazole. Inducers: apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John’s Wort.
- •7) Inadequate organ function including but not limited to:
- •a) Alanine aminotransferase (ALT) > 2x ULN.
- •b) Aspartate aminotransferase (AST) > 2x ULN.
- •c) Bilirubin direct > 1.25x ULN.
- •d) International normalized ratio (INR) > 1.2.
- •e) Clinically significant hepatic impairment defined as a Child-Pugh B or C.
- •f) Estimated glomerular filtration rate (eGFR) <60 mL/min.
- •8) Any clinically significant comorbidity or systemic dysfunction that, in the opinion of the Investigator, would jeopardize the safety of the subject by participating in the trial.
- •9) History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator.
- •10) Known hypersensitivity to KVD824 or placebo or to any of the excipients.
- •11) Any prior use of any gene therapy treatment for HAE.
- •12) Participation in any interventional investigational clinical trial within 4 weeks of the last dosing of investigational drug prior to screening.
- •13) Any pregnant or breastfeeding subject.
研究者
相似试验
进行中（未招募）
1 期
A clinical study (Phase III) to assess the Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT), when compared against placebo in a randomised, double blind manner.CMV reactivation after allogeneic stem cell transplantation.MedDRA version: 20.0Level: LLTClassification code 10049107Term: CMV viraemiaSystem Organ Class: 100000004862EUCTR2013-000903-18-DEAstellas Pharma Global Development, Inc. (APGD)514
进行中（未招募）
1 期
A clinical study (Phase III) to assess the Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT), when compared against placebo in a randomised, double blind manner.CMV reactivation after allogeneic stem cell transplantation.MedDRA version: 19.1Level: LLTClassification code 10049107Term: CMV viraemiaSystem Organ Class: 100000004862EUCTR2013-000903-18-SEAstellas Pharma Global Development, Inc. (APGD)500
进行中（未招募）
1 期
An experimental study in men and women with head and neck cancer to test the safety, tolerability and the effects of addition of a vaccine directed against an infection with Human Papilloma virus Type 16 (HPV16) in combination with an antibody that activate part of the immune systemHPV16-Positive Oropharyngeal Cancer (OPC)MedDRA version: 21.0Level: PTClassification code 10031098Term: Oropharyngeal cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000789-13-DEISA Therapeutics B.V.194
进行中（未招募）
1 期
A clinical trial looking at the use and safety of tadalafil for the treatment of Duchenne Muscular Dystrophy in children.MedDRA version: 16.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2013-001194-25-ESilly S.A.306
进行中（未招募）
1 期
Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus RuxolitinibMyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000097-15-GRAbbVie Deutschland GmbH & Co. KG230